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Investigating the Potential Effectiveness of Two Therapeutic Targets, Utrophin and HSP70, in the 
Treatment of Duchenne Muscular Dystrophy 
Daniel Spensieri 
 
Duchenne muscular dystrophy is an incurable, genetic neuromuscular disorder that causes 
progressive, severe muscle wasting in young men and eventually leads to early death. The disease is 
caused by a mutation in the gene encoding the cytoskeletal protein dystrophin, which leads to stress 
induced sarcolemmal tearing. Abnormally high levels of intracellular Ca2+ in muscle cells is a main 
feature of the disorder as it triggers many secondary effects that are detrimental to the proper 
functioning of skeletal muscle. Both utrophin and HSP70 have been suggested to have potential 
therapeutic potential as a result of their preferential expression in the relatively damage-resistant slow, 
oxidative fibres. In my studies, I found that by forcing transgenic expression of the Ca2+ chelator 
parvalbumin in slow fibres, utrophin expression in slow fibres was blunted without altering HSP70 
expression. In this case, the slow fibres showed increased signs of stress and damage therefore 
suggesting that endogenous HSP70 alone may not spare dystrophin deficient muscle fibres. These 
results indicate that utrophin (but not HSP70) is a potential therapeutic target that will prevent muscle 
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1.1 – DUCHENNE MUSCULAR DYSTROPHY 
Duchenne muscular dystrophy (DMD) is the most prevalent genetic neuromuscular disorder in 
the world (1). It is an X-linked disorder affecting 1 in 3600-6000 males (2). Symptoms begin at an early 
age when affected children experience difficulties in walking or stair-climbing. Patients are wheelchair 
bound by their teenage years. Death of DMD patients occurs in the late twenties, usually as a result of 
cardiac or respiratory failure (1, 2). Although modern medicine has extended the life expectancy and has 
made it easier to live with the disorder, there is still no known cure. 
1.1.1 – DMD Etiology 
A mutation in the gene encoding dystrophin is the cause of DMD (3). Dystrophin is a 427-kDa 
cytoskeletal protein predominantly expressed in skeletal and cardiac muscle with smaller amounts also 
found in the brain (3-5). The 2.5 Mb dystrophin gene is located on the X chromosome and is composed 
of 79 exons, making it the largest gene in the human genome (3, 6). The mutation either results in a 
non-functional protein in DMD; or a truncated, yet still functional form of dystrophin in Beckers 
muscular dystrophy; a much less devastating disorder (3, 7). 
Dystrophin is a member of the dystrophin-associated protein complex (DAPC) (8). The DAPC is 
an extensive protein scaffolding complex localized throughout the entire sarcolemma and is important 
in maintaining the structural integrity of the entire muscle fibre (9). The DAPC links extracellular laminin 
protein to the intercellular filamentous actin protein (f-actin) (fig1) (10). In DMD and the murine-model 
equivalent (mdx mouse), muscles are susceptible to stretch and contraction-induced damage (7, 11). 
Healthy muscles have a fairly high regenerative capacity to repair damaged tissue (12), however 
dystrophin-deficient muscle tissue undergoes continuous cycles of degeneration and regeneration which 
eventually exhausts the muscle progenitor pool of satellite cells responsible for repair (13). This 
exhaustion leads to muscle failure as contractile tissue is replaced with inert scar tissue and fatty 
adipose deposits (14). Degeneration-regeneration cycles can be phenotypically identified histologically 
by an increase in centrally located nuclei (CLN) and fibre-size variability (FSV), as well as increases in 




Figure 1 Dystrophin-Associated Protein Complex - adapted from (17) 
Dystrophin binds to cytoskeletal f-actin at its NH2 terminus. At its COOH terminus, dystrophin is associated with dystroglycan which then 
associates with extracellular laminin via the sarcoglycans. Mutations leading to loss of functional dystrophin lead to membrane weakness in 
DMD or a truncated protein at the central rod-domain leads to smaller, but still functional dystrophin protein in the less devastating Becker 
muscular dystrophy. 
 
1.1.2 – Mdx mouse model 
The mdx mouse model of this disease was first discovered when a group of inbred C57BL/10 
mice demonstrated three-fold higher levels of creatine kinase and pyruvate kinase (18). In mdx mice, a 
point mutation in exon 23 on the X chromosome causes a premature stop codon resulting in a 
truncated, non-functional dystrophin protein (18, 19). Contrary to DMD, the lifespan of mdx mice is not 
significantly reduced (20) and they do not display any signs of obvious weakness (21). Muscles from mdx 
mice do however display significant decreases in normalized force and power outputs per unit of muscle 
mass (21). Hindlimb muscles are considered to be less affected in mdx mice since they display relatively 
little fibrotic activity and never display adipose deposition (22). Regenerating fibres hallmarked by CLN 
are mainly seen between 2-4 months of age (22). Skeletal muscles are composed of four different fibre 
type ranging from fast and glycolytic type 2 fibres, to the slow and oxidative type 1 fibres (23). Biopsies 
taken from DMD patients, display that fast muscle fibre types are preferentially affected (24) and the 
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same effect is observed when comparing the fast extensor digitorum longus (EDL) muscle to the slow 
soleus muscle in mdx mice (25).  The pathophysiological differences between human DMD and mdx 
mice are not fully understood however the mdx mouse remains an important model in DMD research. 
1.1.3 –DMD Treatment 
The glucocorticoid therapies used to treat DMD provide limited results and do not prevent early 
death. Glucocorticoids do not decrease membrane fragility but rather decrease secondary inflammation 
caused by damaged muscle fibres (26). More specific therapeutic strategies which prevent fibrosis and 
loss of function of dystrophin-deficient muscles are currently being explored. Several gene therapy 
studies are underway to replace the mutated dystrophin gene with a functional one however major 
hurdles still need to be overcome before this can be achieved (27-29). Large-scale gene therapy 
treatment for DMD may not be clinically available for several years therefore a more promising shorter-
term avenue is to increase endogenous expression of the dystrophin-related protein utrophin, as 
utrophin is homologous to dystrophin in both structure and function  (30, 31). 
1.2 - UTROPHIN-MEDIATED RESCUE 
Utrophin has a spectrin-like central rod domain and binds f-actin at one end and interacts with 
DAPC members at its other end in the same way as dystrophin (31). The main difference between 
dystrophin and utrophin is its localization within the muscle fibre. In healthy muscle fibres, dystrophin is 
located along the length of the sarcolemma while utrophin is restricted to the neuromuscular junction 
(NMJ) and myotendinous junctions (10, 32, 33). In some dystrophin deficient muscle fibres, total 
utrophin expression is increased and its localization is extended beyond the NMJ and myotendinous 
junction, and throughout the sarcolemma (34, 35). 
1.2.1 - Extrajunctional utrophin is found in slower fibre-types 
A connection between utrophin and slow muscle fibre types was first discovered by 
investigating dystrophic extraocular muscles (36). The primarily slow, extraocular muscles, show 
relatively little signs of damage in mdx mice, however in the absence of both utrophin and dystrophin, 
these muscles are severely affected (36). Further investigation via immunofluorence (IF) and in situ 
hybridization experiments in wildtype (WT) soleus (slow) and EDL (fast) muscles revealed extrajunctional 
utrophin localization is specific to the slower type I and IIa fibres (37). An increased utrophin level in 
type 1 fibres is attributed to an increase in mRNA stability in slow muscles (37). The findings of 
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utrophin’s selective extrajunctional presence in slow fibres in conjunction with the fact that slow fibres 
are more resistant to the dystrophic pathology spawned the theory that promoting the slower, more 
oxidative myogene program could attenuate the dystrophic phenotype. Identification of signaling 
pathways which promote this program then became a focal point of DMD research. The calcineurin (Cn) 
signaling pathway is known to promote the slower fibre myogene program (38). 
1.2.2 – Calcineurin/NFAT signaling pathway 
Calcineurin is a Ca2+/Calmodulin (CaM) regulated  serine/threonine protein phosphatase (39). Cn 
enzymatic activity requires a catalytic (CnA) and a regulatory (CnB) subunit (40). The CnA subunit 
includes protein domains conferring catalytic activity, CnB interaction and a CaM-binding site (41). It 
also includes a C-terminal autoinhibitory domain, which blocks the catalytic site and is removed in 
response to Ca+ release (41). Constitutively active CnA (CnA*) -lacks the autoinhibitory domain and CaM-
binding sites- (42) is commonly used to study the role of CnA activity in vitro and in vivo. 
Cn-dependant signaling mechanisms were first characterized extensively in the activation of 
cytokine gene expression in T and B lymphocytes where the binding of Ca2+ to a CaM/Cn complex 
stimulates serine/threonine phosphatase activity of Cn of which dephosphorylates many downstream 
targets (43). The family of Nuclear Factor of Activated T-cells (NFATc1-NFATc4) transcription factors 
represent the major targets of CaM/Cn signaling (fig2) (44). Dephosphorylation of NFAT binding sites by 
Cn removes phosphate groups that mask its nuclear localization signal thereby enabling translocation 
from the cytoplasm to the nucleus, where it binds to, and stimulates transcription of target genes (43-
45). Cn/NFAT activity responds preferentially to sustained low-amplitude intracellular elevations of Ca2+ 
and is insensitive to transient, high-amplitude intracellular oscillations in Ca2+ (43, 46). Similarities 
between Intracellular Ca2+ oscillations found in T and B lymphocytes and those found in skeletal muscle 
upon neuromuscular stimulation pointed to a potential role for Cn/NFAT signaling in skeletal muscle.  
In skeletal muscle, signals from motor neurons trigger the rapid release and uptake of 
intracellular Ca2+ during muscle contraction (47). Tonic motor-nerve activity found in slow muscle fibres 
is characterized at 10-15Hz (48), resulting in sustained, low-amplitude elevations in intracellular calcium 
concentrations [Ca2+]i (49) similar to those found in T lymphocytes. The sustained levels of intracellular 
Ca2+ found in slow fibres is sufficient enough to activate CnA/NFAT signaling (38, 50, 51). Conversely, 
CnA/NFAT signaling does not occur with short bursts of 50Hz stimulation, consistent with those found in 
fast fibres (48, 50). Once activated, CnA/NFAT signaling plays an important role in the determination of 
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skeletal muscle fibre type by promoting the slower, more oxidative myogene program (38, 52, 53). CnA* 
treatment of skeletal myocytes targets expression of the slow fibre gene program promoters, troponin I 
slow (TnIs) and myoglobin, but not the fast muscle creatine kinase (MCK) promoter (38, 54) whereas 
treatment of mice with the CnA blockers, Cyclosporin-A and FK506, induces slow to fast fibre type 
conversions  
1.2.3 - Transgenic alterations of CnA/NFAT signaling 
 As a result of its vast range of signaling targets, several transgenic models of mice have been 
created to alter Cn activity in skeletal muscle in order to better investigate its role in skeletal muscle.  
One model of increased Cn activity, uses CnA* and links it to the MCK promoter (fig2). MCK is 
preferentially expressed in type 2 muscle fibres, this ensures that Cn activity is now present in all 
skeletal muscle myofibrils (52, 55). In order to inhibit Cn activity, another transgenic mouse was created 
which links calmodulin binding peptide (CaMBP) to the TnIS promoter (fig2) (53). CaMBP binds CaM 
thereby inhibiting its activation of Cn. TnIS is specific to type 1 fibres therefore making the transgene 
highly active in these fibres and ensuring a complete silencing of skeletal muscles CnA activity.  
 
Figure 2 Transgenic models used to study CnA Signaling - Adapted from (56) 
1) The CnA* mice express a constitutively active form of Cn in fast fibres thereby increasing CnA/NFAT signaling. 2) In CaMBP 
mice, CnA/NFAT signalling is inhibited by expressing Calmodulin binding peptide in slow fibres. 3) PV mice express Ca
2+
 chelator 
parvalbumin in slow fibres which prevents Ca
2+






1.2.4 - CnA/NFAT promotes utrophin-mediated mdx rescuing 
As a result of CnA’s implication in the slow fibre gene program, expression of utrophin 
transcripts in mice having altered CnA activity was studied and revealed that increased CnA/NFAT 
activity upregulates extrajunctional utrophin expression (fig. 3) (57). Furthermore, electrophoretic 
mobility and supershift assays revealed the presence of a NFATc1 binding site on the utrophin promoter 
and either mutation of the NFAT binding site or CsA/FK506 treatment decreases utrophin expression 
(57, 58). It is therefore theoretically possible that promoting CnA/NFAT activity could stimulate 
extrajunctional utrophin expression and restore sarcolemmal integrity in dystrophin deficient muscles. 
 
Figure 3 Schematic model regulatory events controlling utrophin gene expression adapted from (58) 
Synaptic regions of fast and slow fibres express utrophin. In slow muscle fibres, tonic electrical activity triggers specific patterns 
of Ca
2+
 flux thereby activating the CnA/NFAT signaling pathway. Once dephosphorylated, NFAT is free to travel to myonuclei to 
transactivate the utrophin-A promoter in extrasynaptic (extrajunctional) compartments. This pathway is not active in fast 
muscle fibres, thus explaining the absence of utrophin in their extrasynaptic compartments. 
 
By crossing mdx mice with the mck-CnA* mice, our lab has previously shown that promoting a 
slow fibre gene program was able to rescue the dystrophic pathology as a result of increased CnA/NFAT-
mediated utrophin expression (57, 59). In contrast,  the soleus from mdx mice crossed with TnIS-CaMBP 
mice have decreased CnA signalling, resulting in decreased extrajunctional utrophin expression and an 
exacerbated dystrophic phenotype as measured by an increase in CLN, FSV and collagen infiltration (60). 
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These studies showed not only the therapeutic potential of increased CnA/NFAT signaling but also 
emphasized the role that CnA/NFAT plays in limiting slow fibre damage. 
1.3 – RESTORING CA2+ HOMEOSTASIS HAS THERAPEUTIC POTENTIAL 
An important feature of dystrophin deficient muscles is higher levels of [Ca2+]i (61, 62). Calcium 
homeostasis is critical for the normal functioning of many aspects of muscle function (63). Though the 
genetic defect underlying the disorder is not directly related to Ca2+ activity, disturbed intracellular Ca2+ 
signaling is a significant contributor to the pathology of DMD. The sustained, influx of [Ca2+]i in mdx does 
increase CnA/NFAT activity in slow fibres however it also triggers other unwanted effects such as 
increased inflammatory response (64, 65), increased proteolysis (66) and mitochondrial dysfunction 
(67). The increase in [Ca2+]i is attributed to a combination of three pathomechanisms occurring in 
dystrophin deficient tissue; 1) hyperactive Ca2+ channels (68-70) 2) transient sarcolemmal tearing (11, 
63) and decrease function of Ca2+ handling proteins (71, 72). For this reason, another therapeutic 
avenue of research, independent of utrophin-related research, has developed in recent years which 
moves to restore Ca2+ homeostasis in dystrophic tissue (71, 73-75). 
1.3.1 – HSP70-mediated rescue 
A recent publication by the Lynch group has shown that mdx muscles with forced Heat Shock 
Protein-70 (HSP70) activity either by transgenic mutation or by the pharmaceutical agent BGP-15 show 
less damage (74). They speculated that this occurs as a result of HSP70’s protective role on 
Sarco/Endoplasmic Reticulum-Ca2+-ATPase (SERCA) (74, 76). SERCA is responsible for pumping out large 
amounts of Ca2+ out of the sarcoplasm after muscle contraction (77). As high [Ca2+]i caused by leaky Ca
2+ 
channels is a feature of dystrophin-deficient muscles, preserving SERCA function could theoretically 
correct the [Ca2+]i (74). Interestingly the Lynch group showed that HSP70-mediated rescuing occurred 
independent from utrophin as dystrophin/utrophin dKO mice also showed less signs of damage (74). 
1.3.2 - HSP70 preferentially expressed in type I and IIa fibres 
Heat shock proteins are a set of proteins that are rapidly synthesized in cells in response to 
protein-damaging stresses (78). They are most commonly associated with having a protective role in 
response to heat-related stress (78). Although normally found at lower levels in unstressed skeletal 
muscle fibres, the inducible isoform of the HSP70 family is constitutively expressed in slow fibres (79, 
80). The exact reasoning for this is not fully understood, however it is postulated that the constitutive 
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expression of HSP70 in slow fibres is related to the higher activity levels of these fibre types. Fast to slow 
fibre type remodelling of the rat plantaris muscle induced by functional overload increases  CnA/NFAT 
activity as well as HSP70 expression (52, 79, 81). The strong evidence of HSP70’s localization in slow 
fibres may be a potential explanation for the findings by the Lynch group since slow fibres are already 
known to be resistant to dystrophic phenotype. Furthermore, it could be argued that the improvements 
observed when HSP70 was pharmacologically introduced into dystrophin/utrophin dKO mice were not 
as pathophysiologically significant as other studies aimed at increasing extrajunctional utrophin. No 
changes in contraction-mediated damage, no decrease in inflammatory markers, or functional 
improvements were found upon increased HSP70 expression. Finally, although significant increase in the 
time to death was found in dystrophin/utrophin dKO mice, premature death was still not prevented by 
the pharmacological induction of HSP70 (74). The role for HSP70 in regulating Ca2+ homeostasis and 
rescuing the dystrophic phenotype in mdx mice still remains unclear.  
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2. HYPOTHESIS AND SCIENTIFIC RATIONALE 
2.1 – Scientific rationale 
In order to get a better understanding of the relationship that utrophin and HSP70 may have in 
the rescuing of slow fibres with altered Ca2+ activity, a transgenic line of mdx mice was developed which 
overexpress the Ca2+ buffering protein parvalbumin (PV) in slow type 1 fibres via the TnIS promoter (fig. 
2). Parvalbumin is a high affinity Ca2+-binding protein endogenously expressed in fast type 2 fibres (82). 
Its high affinity to Ca2+ allows for accelerated removal of Ca2+ from the sarcoplasm (83). Altered PV 
function in fast fibres leads to higher intracellular Ca2+ levels and prolonged time required to attain peak 
twitch tension (83). PV overexpression in slow fibres attenuates CnA/NFAT signalling, and leads to 
altered contractile properties of slow twitch muscle, decreased oxidative and glycolytic capacities and 
increased expression of genes related to the fast phenotype without actually altering the MyHC 
composition of the fibres (84). The insertion of the pv TG in dystrophic slow fibres facilitated the study 
of the behaviour of HSP70 in an environment of altered Ca2+ activity as well as decreased CnA/NFAT 
activity along with its downstream target, utrophin. Under these conditions, it was possible to observe 
HSP70’s therapeutic role in protecting dystrophin and utrophin null fibres. 
 
2.2 - Hypothesis 
Altered Ca2+ homeostasis in slow muscle fibres will exacerbate the dystrophic pathology as a 






3. SPECIFIC AIMS 
3.1 Aim 1 
To decrease Cn signaling by altering Ca2+ oscillatory patterns in slow muscle fibres (mdx/pv 
model). 
3.2 Aim 2 
To measure the volume of damaged fibres as a result of the absence of extrajunctional utrophin 
in mdx/pv mice 
3.3 Aim 3 






4.1 - Animal Care Protocols 
All animal protocols were carried out in accordance with the guidelines of the Canadian 
Council for Animal Care. These procedures were approved by the University Animal Research 
Ethics Committee (UAREC) of Concordia University. Transgenic mice expressing either PV-HA, 
CnA*, CaMBP were crossbred with mdx mice. Transgenic mice were identified by PCR screening 
of genomic DNA isolated from tails. All mice were housed in a room with a twelve hour light 
cycle. 
4.2 - Generation and identification of mdx/pv mice  
To assess the role of [Ca2+]i kinetics in a dystrophin deficient background, mdx mice 
expressing a PV transgene specifically in slow muscle fibers was generated. Previous findings 
have determined that mdx/pv mice are healthy and capable of breeding. PCR-based screening 
was used to identify animals expressing PV-HA transgene as well as mdx mice carrying a 
spontaneous nonsense mutation in exon 23 of the dystrophin gene. Immunoblotting analyses 
of soleus and the primarily fast EDL muscles from WT, pv, mdx and mdx/pv mice (n=3) 
demonstrated the presence of endogenous pv in both soleus and EDL muscles of all mice and 
the expression of PV-HA solely in soleus muscles of PV and mdx/PV mice with no detectable 
levels in EDL muscles (unpublished results). 
4.3 - Mice Genotyping 
Genomic DNA was isolated from 5mm clippings of 6 week old mouse tails. Briefly, tail 
clippings were left to digest overnight at 55oC in a mix of lysis buffer and proteinase K solution. 
DNA was then purified using a phenol/chloroform isolation method. Amplification was 
performed by polymerase chain reaction as described previously for the following targets: mdx 
(85), PV-HA (84), CnA* (59) and CaMBP (60). Genotyping primers are listed in table 1. 
4.4 - Animal surgeries and tissue extraction 
Tissues from mdx mice were extracted at 10-14 weeks of age. All surgical procedures 
were performed under aseptic conditions on animals anesthetized by intramuscular injection 
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(1.2 μl/g) of 100 mg/ml ketamine hydrochloride (Ketalean, CDMV, Canada) and 10 mg/ml 
xylazine (rompun, CDMV, Canada) in a volume ratio of 1.6:1.0. Bilateral soleus and GAS samples 
were excised and embedded in frozen tissue mounting medium (Neg-50, Thermo Scientific, 
Canada) and frozen in a pool of melting isopentane cooled in liquid nitrogen. The mice were 
then euthanized via cervical dislocation. Tissues were stored at -80oC until processed. 
 
4.5 - Assessment of NFATc1 Nuclear Localization 
Assessment of NFATc1 nuclear localization was performed as previously described (59). 
Briefly, soleus muscle cross-sections (10µm thick) were fixed with 4% paraformaldehyde (PFA), 
blocked and permeabilized with 2% goat serum and 0.2% Triton X-100, then washed with 1X 
phosphate buffer saline (PBS) and incubated with rabbit anti-NFATc1 (sc-13033, Santa Cruz, 
USA) at 4o overnight. After washing, sections were incubated with goat anti-rabbit IgG Alexa-
546 (Invitrogen, Canada) for one hour, then washed and mounted with Vectashield containing 
1.43nM 4',6-diamidino-2-phenylindole (DAPI) (Vector laboratories, Canada) for nuclear staining. 
Quantification of NFATc1 nuclear localization was performed by counting the number of 
myonuclei positively stained for NFATc1 in cross sectional views of myofibers and calculating 
the percentage of nuclear NFATc1 (n=3).  
4.6 - Assessment of Central Nucleation and Muscle Fiber Size Variability 
Degeneration and regeneration of soleus muscles from mdx and mdx/pv mice was 
assessed by examining the percentage of fibers displaying central nucleation using the 
Hematoxylin and Eosin (H&E) stain-counterstain method. Hematoxylin stains the nucleus 
purple, whereas eosin stains the cytoplasm pink. 10µm cross sections from soleus muscles were 
stained for 5mins in a Hematoxylin solution and then counterstained for 3mins in an Eosin 
solution. Sections were then dehydrated in a series of ethanol solutions, cleared with xylene 
and mounted using permount mounting medium (Fisher Scientific, Canada). The sections were 
visualized using a standard halogen light microscope, where 2-3 10x images per soleus section 
were captured so as to represent the entire area of the soleus without acquiring overlapping 
areas. A percentage of fibres displaying central nucleation (CLN) was then quantified using the 
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following formula;                    
                
            
 (n=3). Fibre size variability was 
assessed as previously described (86) by using the variance coefficient between fibres of a given 
section using the following formula; 
                     
                                      
                     
 (n=3). 
4.7 - Immunofluorescence Experiments 
Serial cryosections (9µm) of soleus and GAS midbellies were captured onto superfrost 
plus slides (VWR, Canada) and stored in a humid chamber until usage. Sections were fixed in 
cold acetone for 10mins and then washed 2x5 mins in 25mM PBS. Sections were then blocked 
in either 5% goat serum or mouse on mouse blocking reagent (M.O.M staining standard kit, 
Vector Laboratories, Canada) for 1h. Sections were washed 2x2 mins in PBS or M.O.M diluent 
followed by 30 min primary antibody incubation with either rabbit anto-HSP70: SPA-812 (Enzo 
Life Sciences, USA) 1:50 or mouse anti-utrophin: DRP3/20C5 (Leica biosystems, Canada) 1:200. 
Sections were then washed 3x5 mins in PBS followed by secondary antibody incubation for 
10mins with either biotinylated anti-mouse IgG or biotinylated anti-rabbit IgG (Vector 
Laboratories). This was followed by another PBS wash and 5 minute incubation with 
streptavidin-Dylight 594 (Vector laboratories, Canada).  
Separate serial sections were also incubated overnight with the following primary 
antibodies: mouse anti-Serca1: MA3-912 (Thermo Scientific, Canada) 1:200; mouse anti-Serca2: 
MA3-919 (Thermo Scientific, Canada) 1:200; mouse anti-MyHC I: A4.840, (DSHB, USA) 1:25; 
mouse anti-MyHC IIa: SC71 (DSHB, USA) 1:10 or mouse anti-MyHC IIb: BF-F3 (DSHB, USA) 1:10. 
Sections were then washed 6x5 mins followed by secondary antibody incubation for 2 hours 
with either goat anti-mouse IgG Alexa-488 or goat anti-mouse IgM Alexa-546 (Invitrogen, 
Canada) 1:500 for Serca1/2 or 1:25 for the MyHC’s.  
All slides were then washed extensively in PBS and air dried for 30mins. Coverslips were 
then mounted with Vectashield mounting medium containing 1.43nM DAPI (Vector 
Laboratories, Canada). Coverslips were sealed with nail polish and slides were stored at 4oC. 
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Control experiments omitting primary antibodies revealed absent or very low-level 
background staining (fig. S1). Antibody specificity of the polyclonal HSP70 was also verified with 
two other monoclonal antibodies (fig. S1). 
 
4.8 - Immunofluorescent Image Analysis 
Images were acquired on an Olympus BX-60 fluorescent microscope (Olympus) using 
the same exposure settings between sets. All analyses were performed using Image-pro 6.2 
software (Olympus, Canada). 
For all analyses in soleus muscles, three randomly selected areas per set of either mdx 
or mdx/pv were analyzed for protein expression of MyHC I, MyHC IIa, and utrophin as well as 
localization of nuclear DAPI staining (n=3). For all analyses in GAS muscles, three areas per set 
of either mdx, mdx/pv, mdx/CnA* or mdx/CaMBP were selected only under the condition that 
they have at least one representative fibre of each fibre type. Areas were then analyzed for 
protein expression of MyHC I, MyHC IIa, MyHC IIb, HSP70, utrophin, as well localization of 
nuclear DAPI staining (n=2). Serca1 and Serca2 were also assessed in mdx and mdx/pv samples 
(n=1). 
 
4.9 - Statistical analysis 
Statistical analyses were performed using the SPSS software program version 17.0. (IBM 
SPSS, USA). Results were expressed as means ± SEM. Independent samples T tests assuming 















































5.1 - Mdx/pv mice have decreased CnA/NFAT signaling and increased dystrophic phenotype 
Dystrophin-deficient mdx mice were inserted with a transgene that preferentially 
expresses pv in type 1 fibres via the TnIS promoter (fig. 2), in order to assess the role of calcium 
kinetics. In WT mice, the TG displayed Cn activity levels that were 36% of their WT counterparts 
(84). Although in the current study, calcineurin phosphatase activity was not directly assayed, it 
was indirectly measured via IF experiments of the downstream target NFATc1 (fig. 4A). For this 
purpose, the primarily slow mdx and mdx/pv soleus muscles were studied, as this is where the 
TG is known to be most active based on the high levels of TnIS. Since dephosphorylated NFATc1 
is shuttled to the nucleus, the quantification of how many nuclei expressing NFATc1 is a reliable 
indication of NFATc1 activity. As predicted, nuclei from mdx/pv soleus muscles had 34% of 
activated NFATc1 compared to mdx mice (fig. 4A) (87). 
The next step was to confirm whether this decrease in CnA activity exacerbated the 
dystrophic phenotype. The number of centrally located nuclei in mdx soleus is reported to be  
just over 60% between 8-13 weeks of age (20). Similar results were found in this study, with 
63% of fibres from the mdx soleus displaying CLN. As hypothesized, a significantly larger 
number of fibres with CLN were found in the mdx/pv soleus (81%) (fig. 4B).  
Another histological indicator of damage in dystrophin deficient mice is the fibre-size 
variability in the cross-sectional area of fibres. Generally, mdx muscles have a variance 
coefficient double that of their WT counterparts (86). Surprisingly, no significant difference in 
the FSV was observed in the presence of the pv TG (4C). 
Overall, the results suggest that the pv TG altered the Ca2+ kinetics of mdx mice and 
decreased CnA signaling activity enough to exacerbate the dystrophic pathology, however, the 




Figure 4. Characterization of mdx/pv model 
Forced expression of the pv transgene in slow muscle fibres results in decreased CnA/NFAT signaling and 
increased markers in damage.  (A) Representative photomicrographs showing a decrease in NFATc1 nuclear 
localization. Arrows indicate nuclei positively co-staining with NFATc1. Panel on the right shows the 
quantification (performed by Dr. Al Zein) of the percentage of nuclei staining positive for NFATc1 (relative to 
mdx). Scale bar, 20µm. (B) Representative photomicrographs and quantification of H&E stains showing an 
increase in the percentage of fibres displaying centrally located nuclei. (C) Representative photomicrographs 
and quantification of H&E stains showing no significant difference in the fibre size variability between mdx 




5.2 - Mdx/PV soleus have decreased utrophin and more damage 
Immunofluorescence stains were then performed in serial cross-sections of soleus 
muscles to confirm that the pv TG also affects utrophin levels of mdx/pv mice. The soleus was 
studied as it is comprised of approximately 50% type I fibres (89), therefore making the TG 
highly active in this muscle. In addition to its high proportion of slow fibres, the soleus’ function 
as a weight bearing muscle increases the risk of stress-induced damage when compared to 
other slow muscles such as the extra-ocular muscles. All fibres within a randomly selected area 
were first analyzed for their presence of either MyHC I or MyHC IIa (fig. 5). Next, serial sections 
of the fibres were analyzed for the presence of extrajunctional utrophin. As predicted, a 
qualitative difference in the amount of extrajunctional utrophin seen in the mdx soleus 
compared to their transgenic counterparts with the latter displaying less (fig. 5). Furthermore, 
an increase in the number of type I fibres displaying CLN was observed in mdx/pv mice (fig. 5). 
These results confirm previous findings that dystrophin deficient mice with decreased 
CnA/NFAT signaling display decreased levels of utrophin and show increased signs of damage 




5.3 – Mdx fibres are still damaged in the presence of HSP70 but not utrophin 
It was then determined if HSP70 could rescue dystrophic fibres in the absence of 
utrophin. To verify this, the “mixed-fibre” GAS muscle was used. Since it is already known that 
HSP70 is present in the slower type I and IIa fibres but not the faster IIb fibres, it was then 
possible to assess whether there was a difference in the number of damaged utrophin-deficient 
fibres in the presence or absence of HSP70. The fast IIb fibres served as an internal negative 
control for both utrophin and HSP70 staining as well as a positive control for damaged fibres in 
both mdx and mx/pv mice. For this analysis, type I and IIa fibres were grouped together and 
termed as type “IIb-negative” fibres, as has been previously performed (59). 
All fibres within a given capture-frame were analyzed for their presence of either MyHC 
I, MyHC IIa or MyHC IIb with any unstained fibres assumed as IIx fibres. To ensure that no other 
Figure 5.  Decreased utrophin expression in mdx/pv mice results in more damage 
Representative photomicrographs of serial crossections from mdx and mdx/pv soleus muscles. In 
the mdx soleus, the majority of type I fibres display extrajunctional utrophin and are resistant to 
damage hallmarked by a lack of centrally located nuclei as demonstrated by (*). Mdx/pv soleus type 
I fibres do not display extrajunctional utrophin resulting in an increased number of centrally located 




compensatory mechanisms to restore normal Ca2+ levels in slow fibres had occurred, fibres 
were also assessed for the presence of either SERCA1 or SERCA2. No difference in SERCA 
isoforms was observed between mdx and mdx/pv mice, with type I fibres displaying SERCA2 
expression and type II fibres displaying SERCA1 expression (fig. 6). As expected, the majority of 
type IIb fibres were positive for damage in both mdx and mdx/pv mice with no noticeable 
difference between the two groups. As previously shown in the mdx GAS (57), extrajunctional 
utrophin was present in all MyHC IIb-negative fibres (fig. 6A). Similar to the soleus muscle, 
forced expression of pv in slow fibres of the GAS muscle also resulted in a decrease in 
extrajunctional utrophin expression (fig. 6B). Finally HSP70 localization was observed and 
revealed no difference in mdx/pv compared to their mdx counterparts, with all IIb-negative 
fibres staining positive for HSP70 (fig. 6).  
Finally, all IIb-negative fibres were assessed for the presence of CLN. In the mdx GAS, 
IIb-negative fibres displayed both extrajunctional utrophin and HSP70 and were resistant to 
damage. Alternatively, the utrophin-deficient IIb-negative fibres found in mdx/pv mice, showed 




Figure 6. IIb-negative fibres are not rescued by HSP70 in the Absence of Utrophin 
Representative photomicrographs of serial sections of mdx (A) and mdx/pv (B) “mixed-fibre” GAS muscle. 
The top four panels display the MyHC isoform of each fibre in which unstained fibres can be assumed to be 
IIx fibres. The MyHCIIb/DAPI merge shows that the majority of type IIb fibres have centrally located nuclei in 
both mdx and mdx/pv mice. In mdx mice, a relatively small portion of MyHC IIb-negative fibres display 
centrally located nuclei however in mdx/pv mice, a larger portion have centrally located nuclei present 
(indicated by arrows). All IIb-negative fibres are also positive for both utrophin and HSP70 in mdx mice 
however in mdx/pv mice, IIb-negative fibres are positive for HSP70 but have no extrajunctional utrophin. 
Bottom two panels show no difference in SERCA distribution in which Serca2 is found only in type I fibres 
whereas Serca1 is found in all type II fibres. Mdx: n=3 (n=1 for SERCA IFs); mdx/pv: n=1. 
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5.4 – Extrajunctional Utrophin Rescues IIb Fibres Despite the Absence of HSP70 
Ca2+ has a wide variety of signaling targets in skeletal muscle therefore it was 
important to confirm the findings from the mdx/pv crosses by also performing similar IF 
stains in other well-known models of altered CnA/NFAT signaling. The two models used in 
this study target CnA/NFAT signaling more directly without affecting the Ca2+ oscillatory 
patterns.  
The first model used was the mdx/CaMBP crossbreeds, which are already known to 
decrease extrajunctional utrophin expression and exacerbate the dystrophic phenotype 
(60). The CaMBP TG blunts CnA/NFAT signaling in slow fibres more effectively than the pv 
TG by binding to, and inhibiting the catalytic domain of CnA thereby preventing 
dephosphorylation of NFATc (fig. 2). As previously described (60), the CaMBP TG decreased 
extrajunctional utrophin expression in IIb-negative fibres (fig. 7C). Similar to mdx/pv mice, 
the IIb-negative fibres of mdx/CaMBP mice also displayed increased damage compared to 
mdx mice despite expressing high levels of HSP70 (fig. 7). 
The second model used was the mdx/CnA* crossbreeds, which are already known to 
increase extrajunctional utrophin expression and ameliorate the dystrophic phenotype. The 
CnA* TG is active in all type II fibres therefore CnA/NFAT signaling is activated in all four 
fibre-types (fig. 2). Studying this model provided access to dystrophic fibres that displayed 
extrajunctional utrophin but relatively little HSP70 for the purpose of assessing damage. As 
predicted, an increase in extrajunctional utrophin was observed in IIb fibres of mdx/CnA* 
mice however HSP70 remained localized in IIb-negative fibres (fig. 7B). This resulted in a 
decrease in the number of damaged IIb fibres despite the absence of HSP70 (fig. 7). 
All together these results confirm that the exacerbation of the dystrophic phenotype 
observed in mdx/pv mice is a result of decreased CnA/NFAT signaling and not likely from 
another Ca2+ signaling mechanism. It also indicates that endogenous levels of HSP70 do not 








Figure 7. Directly Targeting Cn/NFAT Signaling Shows Similar Results 
Representative photomicrographs of serial sections from the “mixed-fibre” GAS of mdx (A) 
and two previously characterized models of altered Cn/NFAT signaling. The mdx/CnA* model 
(B), expresses activated CnA in fast fibres resulting in a larger number of type IIb fibres to 
express extrajunctional utrophin with no changes in HSP70 expression. An increased number 
of type IIb fibres show no signs of damage as indicated by (*). The mdx/CaMBP model (C) 
directly inhibits CnA activity in slow fibres without altering Ca2+ oscillations. MyHC IIb-negative 
fibres do not display extrajunctional utrophin but still express HSP70. There is an increase in 
the number of IIb-negative fibres with centrally located nuclei as indicated by arrows. mdx: 




6.1 – Forced PV in Slow Muscle Fibres Exacerbates the Dystrophic Phenotype 
The maintenance of Ca2+ homeostasis is essential for the proper functioning of skeletal 
muscles however it is disrupted in dystrophin deficient muscles (63, 90). Restoring normal Ca2+ 
transients in dystrophic muscles can protect muscle fibres from stress induced damage (71, 73, 
90). Although excessive Ca2+ entry can have adverse effects in muscle fibres (63), dystrophic 
slow fibres are particularly resistant to this effect, in part, due to the activation of the Ca2+ 
sensitive CnA/NFAT pathway under these conditions (37, 38). The forced expression of pv in WT 
slow muscle fibres effectively disrupts the slow and sustained Ca2+ oscillatory patterns that are 
characteristic of slow muscle fibres and subsequently decreases CnA activity by over 60% (84). 
In this study, CnA/NFAT activity was indirectly measured in mdx/pv mice and a similar result 
was observed (fig. 4). Measuring dephosphorylated, nuclear NFAT levels is not as accurate as 
directly assaying CnA activity since other factors may influence levels of NFAT activity (44). The 
reduced NFATc1 nuclear localization in mdx/PV soleus muscles could, in part, be explained via 
activation of MAPK-JNK1 pathway. Altered Ca2+ levels can also activate other transcriptional 
factors, including stress-activated MAPK-JNK1 pathway (91, 92). Increased JNK1 activity 
increases interactions with NFATc1 and results in its dislocation from the nucleus (93). Overall, 
the decrease in nuclear NFAT observed in mdx/pv mice was similar to WT mice with the 
transgene (84). Therefore the decrease in nuclear NFAT was likely a result of decreased CnA 
activity. 
As hypothesized, altering Ca2+ homeostasis in dystrophic slow muscles increased the 
number of damaged fibres (fig. 4). It did not however, increase the fibre size variability, another 
phenotypic histological indicator of damage in mdx muscles. This can be explained by two 
possible reasons; 1) CnA activity in mdx/pv mice is not completely blocked therefore the 
measurement of CLN may be more sensitive than FSV in these mice and 2) the age of the mice 
used in the study. Although the progression of the disease in mdx mice is slower in the soleus, it 
is still progressive and certain stress markers such as FSV are already plateaued at 12 weeks of 
age (20). It is possible that the fibre size variability may have progressed and plateaued earlier 
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in the life cycle of the mdx/pv mice however at three months of age, as studied here, both mdx 
and mdx/pv mice had similar levels of fibre size variability. 
It is widely accepted that extrajunctional utrophin expression can prevent stress-
induced damage in slow fibres (30, 36, 37). In the current study, co-staining between MyHC I, 
MyHC IIa and utrophin confirmed that only the type I fibres display extrajunctional utrophin in 
the mdx soleus. Furthermore, significantly less fibres displayed CLN when extrajunctional 
utrophin was expressed compared to when utrophin expression was limited to the NMJ thereby 
confirming previous results (37, 59). In agreement with the decreased NFATc1 nuclear 
localization found in mdx/pv mice, a decrease in extrajunctional utrophin was observed not 
only in IIa fibres but also type I fibres. This resulted in an increase in the number of type I fibres 
displaying CLN in the mdx/pv soleus compared to the mdx soleus. Taken together, this suggests 
that disrupted Ca2+ oscillatory patterns in slow muscle fibres results in an increased risk of 
stress-induced damage, largely as a result of impaired CnA/NFAT signaling and its downstream 
target, utrophin.  
Altered Ca2+ homeostasis can also have effect on other signaling pathways including the 
Ca2+ sensitive protease calpain (63, 94). Calpain selectively degrades key proteins in the Ca2+ 
cycle and is involved in several muscle diseases including limb-girdle muscular dystrophy type 
2A (95). In this context it is theoretically possible that altered calpain activity as a result of the 
pv TG in mdx mice could also account for the increase in damage found in both soleus and GAS 
tissues. Although no measurement of calpain activity was conducted in this study, two other 
well characterized models of altered CnA/NFAT signaling were looked at in mdx mice, neither of 
which alter Ca2+ homeostasis and by association, calpain activity. In these models, results 
similar to the mdx/pv data were observed (fig. 7); therefore confirming that the increase in 
damage found in mdx/pv mice was likely a result of decreased CnA/NFAT activity. 
6.2 – HSP70’s Therapeutic Role is Dependant on Extrajunctional Utrophin Expression 
It has been recently suggested that the pharmacological induction of HSP70 can 
ameliorate the dystrophic phenotype (74) however no evidence was found in the current 
investigation that supports this claim. Results from IF experiments, in agreement with previous 
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data, show that type IIb-negative fibres are more resistant to the dystrophic phenotype in the 
mixed-fibre GAS. Furthermore, HSP70 was consistently found in IIb-negative fibres, confirming 
previously found data on the location of HSP70 expression in skeletal muscle tissue (81, 96). 
Since both HSP70 and utrophin are present in the rescued IIb-negative fibres, a comparison was 
performed to identify whether rescued fibres are more closely associated with the presence of 
HSP70 or extrajunctional utrophin. As hypothesized, the absence of utrophin resulted in a large 
proportion of damaged fibres however no obvious increase in the number damaged fibres was 
observed in the absence of HSP70. This can partly be explained by the proposed therapeutic 
roles that each utrophin and HSP70 are suggested to assume. While utrophin functionally 
replaces dystrophin in the DAPC therefore restoring sarcolemmal strength, HSP70 is suggested 
to limit secondary complications found as a result of stress-induced membrane tearing (30, 74). 
Transgenic overexpression of HSP70 in mdx mice does not improve muscle fibre structural 
integrity (74). The fact that more fibres with CLN are found in the mdx/pv mice despite 
sustained HSP70 expression may indicate that dystrophin deficient fibres have a stronger 
necessity for the restoration of membrane integrity (via extrajunctional utrophin expression) 
rather than a limitation of secondary effects caused by membrane tearing as is suggested of 
HSP70’s therapeutic role. Overall, the preliminary IF data suggests that the potential 
therapeutic effects of HSP70 in muscular dystrophy may only be a small member of a 
collaborative effort of the slower, more oxidative muscles fibres. 
HSP70 may still have a therapeutic role in ameliorating the dystrophic phenotype since 
it also acts as a molecular chaperone protein that inhibits inflammatory mediators including the 
aforementioned p-JNK (97) as well as the pro-inflammatory cytokines tumor necrosis factor-α 
(TNF-α) and nuclear factor-κB (NF-κB) (98). Although TG overexpression of HSP70 in mdx mice 
does not decrease p-JNK or NF-κB activity, it does decrease mRNA expression of macrophage 
markers CD68 and F4/80 as well as expression of TNF-α (74). Since inflammation promotes 
degradation in mdx mice (64), it is possible that HSP70 can be used in combination with other 
therapeutic remedies to ameliorate muscle phenotype in DMD however current glucocorticoid 
treatments are more effective at decreasing inflammation and are already approved for 
treatment of people with DMD (26). 
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HSP70 was also suggested to improve SERCA function as it is known to bind SERCA and 
prevent functional deactivation under cellular stress (74, 76).  Improved SERCA function 
regulates Ca2+ homeostasis and therefore prevents degeneration of dystrophic muscle (71). The 
current study shows no difference in the expression of SERCA isoforms between mdx and 
mdx/pv mice as shown by preliminary immunofluorescent stains (fig. 6) as well as by western 
blotting (unpublished results). Although no difference in SERCA protein expression was found, 
the limitations of the techniques used to measure expression are not sensitive to SERCA activity 
levels. In mdx mice, SERCA activity decreases compared to WT mice, largely due to post-
translational modifications such as nitrosylation, which decrease maximal SERCA activity as a 
result of changes in Ca2+ binding and ATP-binding domains (76). It is possible that there is a 
difference in max SERCA activity in mdx/pv mice despite having similar expression patterns to 
mdx mice. In this case it would be important to further investigate whether HSP70 helps to 





 Collectively, the current results emphasize a need to restore skeletal muscle membrane 
integrity in DMD. Although the restoration of Ca2+ homeostasis does improve dystrophin-
deficient muscle function, it does not prevent membrane tearing caused by sarcolemmal 
structural weakness. Dystrophin-related protein utrophin upregulation continues to be a 
primary therapeutic candidate.  Unfortunately, utrophin upregulation via the CnA/NFAT 
signaling pathway is not pharmacologically possible as a result of calcineurin’s important 
functions elsewhere in the body, namely in the heart and immune system. It is therefore more 
important to pursue other avenues which increase CnA/NFAT signaling in muscle indirectly by 
promoting a fast to slow fibre-type conversion. Various other targets have been shown to 
promote the fast to slow fibres type conversion and ameliorate the dystrophic phenotype in 
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Figure S1. Polyclonal Antibody is Specifically Found in 2b –negative fibres 
Representative photomicrographs taken with a 10X objective lens of serial sections from the “mixed-fibre” GAS of 
WT mice testing the specificity of the polyclonal AB used in these experiments. The polyclonal Ab was tested 
alongside two different monoclonal Ab’s and displayed similar staining patterns in which each Ab co-stained with 
2b-negative fibres. Separate serial sections were also captured and followed the same staining procedure with no 
primary Ab and displayed no specific staining pattern. n=2. 
